TITLE

Tranexamic Acid Tablets

AUTHOR(S)
Cada, Dennis J.; Levien, Terri L.; Baker, Danial E.
PUB. DATE
May 2010
SOURCE
Hospital Pharmacy;May2010, Vol. 45 Issue 5, p393
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article provides information on Lysteda or tranexamic acid tablets from Xanodyne, indicated for the treatment of cyclic heavy menstrual bleeding. The drug is a synthetic lysine amino acid derivative antifibrinolytic and has been available over-the-counter (OTC) in Sweden for over 10 years. Also noted are the drugs' pharmacokinetics, comparative efficacy, adverse reactions, and drug interactions.
ACCESSION #
51284601

 

Related Articles

  • The use of tranexamic acid in major joint replacement. Borisov, D. B.; Kirov, M. Y. // Surgery News / Novosti Hirurgii;2013, Vol. 21 Issue 4, p107 

    The literature review of researches devoted to the use of fibrinolysis inhibitors to reduce perioperative blood loss, particularly tranexamic acid in endoprothesis of large joints is presented in this paper. Analysis of the literature showed that sufficient number of evidences of tranexamic acid...

  • New option available for heavy menstrual bleeding.  // Contraceptive Technology Update;Mar2010, Vol. 31 Issue 3, p30 

    The author reports that the U.S. Food and Drug Administration (FDA) has approved the antifibrinolytic drug Lysteda for heavy menstrual bleeding.

  • XenoPort Partners Early Stage Candidate In $147M Deal.  // BioWorld Today;10/16/2007, Vol. 18 Issue 201, p4 

    The article presents information on the partnership of a preclinical candidate for menorrhagia from XenoPort with Xanodyne Pharmaceuticals Inc. Xanodyne has the U.S. rights to develop and commercialize XP21510, a transported prodrug of tranexamic acid for menorrhagia. Based on the deal, XenoPort...

  • Tranexamic acid reduces the risk of death in trauma patients at risk of major bleeding. Wilson, Philip // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;6/19/2010, Vol. 340 Issue 7760, p1327 

    The article presents the findings of a clinical trial conducted in 2010 which demonstrated that administration of tranexamic acid, an antifibrinolytic drug, to trauma patients at risk of major bleeding reduces all cause mortality as well as mortality from bleeding.

  • Can Topical Application of Tranexamic Acid Reduce Blood Loss in Thoracic Surgery? A Prospective Randomised Double Blind Investigation Dell’Amore, Andrea; Caroli, Guido; Nizar, Asadi; Cassanelli, Nicola; Luciano, Giulia; Greco, Domenico; Dolci, Giampiero; Bini, Alessandro; Stella, Franco // Heart, Lung & Circulation;Nov2012, Vol. 21 Issue 11, p706 

    Objective: The systemic or topical use of antifibrinolytic agents is effective in reducing postoperative bleeding and blood product transfusion in cardiac surgery. We sought to study the effect of the topical application of tranexamic acid into the pleural space to reduce postoperative bleeding...

  • Thrombin Activable Fibrinolysis Inhibitor (TAFI): Molecular Genetics of an Emerging Potential Risk Factor for Thrombotic Disorders. Boffa, M.B.; Nesheim, M.E.; Koschinsky, M.L. // Current Drug Targets - Cardiovascular & Haematological Disorders;Dec2001, Vol. 1 Issue 2, p59 

    The balance between the activities of the coagulation and fibrinolytic cascades is crucial for normal hemostasis. However, imbalances can lead to pathological thrombotic events, as is observed in heart attacks and strokes, as well as excessive bleeding, as in hemophilia. Recent investigations...

  • LNG-IUS and Nuisance Bleeding. Allen, Rebecca H. // OB/GYN Clinical Alert;Jul2013, Vol. 30 Issue 3, p20 

    The author discusses a research study conducted to determine the treatment of bleeding accompanying contraceptive action of levonorgestrel intrauterine system (LNG-IUS) which showed that placebo drugs were better in controlling unscheduled bleeding than tranexamic acid and mefanamic acid .The...

  • Tranexamic acid, giving fluids first reduce the need for transfusion in arthroplasty. Blisard, Renee // Orthopedics Today;Feb2012, Vol. 32 Issue 2, p30 

    The article discusses the highlights of a presentation by Stryker Orthopaedics consultant Mark W. Pagnano on reducing blood loss and the need for transfusion in patients undergoing hip or knee arthroplasty, at the Current Concepts in Joint Replacement 2011 Winter Meeting.

  • lys.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1383 

    A definition of the term "lys," which refers to lysine, is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics